DA Davidson Cuts USANA Health Sciences (NYSE:USNA) Price Target to $35.00

USANA Health Sciences (NYSE:USNA) had its price objective cut by DA Davidson from $38.00 to $35.00 in a report issued on Wednesday, Benzinga reports. They currently have a neutral rating on the stock. DA Davidson also issued estimates for USANA Health Sciences’ Q4 2024 earnings at $0.49 EPS, FY2024 earnings at $2.45 EPS and FY2025 earnings at $2.23 EPS.

Separately, StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

USANA Health Sciences Stock Performance

Shares of NYSE USNA opened at $36.81 on Wednesday. The stock has a market cap of $701.27 million, a price-to-earnings ratio of 11.47, a PEG ratio of 1.15 and a beta of 0.89. The business has a 50 day simple moving average of $37.90 and a 200 day simple moving average of $42.44. USANA Health Sciences has a 52 week low of $34.15 and a 52 week high of $54.81.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.49 by $0.07. The business had revenue of $200.22 million during the quarter, compared to analysts’ expectations of $208.45 million. USANA Health Sciences had a return on equity of 10.80% and a net margin of 6.30%. During the same quarter in the previous year, the business posted $0.59 EPS. On average, analysts predict that USANA Health Sciences will post 2.5 EPS for the current year.

Insiders Place Their Bets

In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the sale, the director now owns 2,503 shares of the company’s stock, valued at $111,208.29. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Paul A. Jones sold 6,266 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Turman Fleming sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the transaction, the director now owns 2,503 shares of the company’s stock, valued at approximately $111,208.29. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,940 shares of company stock valued at $311,670 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Assenagon Asset Management S.A. lifted its holdings in shares of USANA Health Sciences by 13.5% during the third quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company’s stock worth $4,702,000 after buying an additional 14,756 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of USANA Health Sciences by 14,068.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock valued at $1,472,000 after purchasing an additional 38,547 shares in the last quarter. Creative Planning acquired a new position in shares of USANA Health Sciences in the third quarter valued at $394,000. Exchange Traded Concepts LLC raised its stake in shares of USANA Health Sciences by 4.4% in the third quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock valued at $292,000 after purchasing an additional 322 shares in the last quarter. Finally, Unison Advisors LLC acquired a new position in shares of USANA Health Sciences in the third quarter valued at $683,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.